Beta-Blockers in COPD: A Methodological Review of the Observational Studies

References

• Sin DD, Man S. A curious case of beta-blockers in chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10):849–850.
   PubMedGoogle Scholar
• Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018;27(149).pii: 180057. doi:10.1183/16000617.0057-2018.
   Google Scholar
• DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D'Ascenzo F, Cerrato E, Biondi-Zoccai G, Lavie CJ, Bell DS, O'Keefe JH. β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart. 2015;2(1):e000230. doi:10.1136/openhrt-2014-000230.
   PubMed Web of Science ®Google Scholar
• Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, Collins PD, Packer M, Wikstrand J, Coats AJ, et al. Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ. 2016;353:i1855.
   PubMedGoogle Scholar
• Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. Eur Respir J. 2016;48(3):880–888.
   PubMed Web of Science ®Google Scholar
• Maltais F, Buhl R, Koch A, Amatto VC, Reid J, Grõnke L, Bothner U, Voß F, McGarvery L, Ferguson GT. β-Blockers in COPD: a cohort study from the TONADO research program. CHEST. 2018;153(6):1315–1325.
   PubMed Web of Science ®Google Scholar
• Dransfield MT, McAllister DA, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Gallot N, Martinez FJ, Scanlon PD, et al. β-blocker therapy and clinical outcomes in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk. An observational substudy of SUMMIT. Ann Am Thorac Soc. 2018;15(5):608–614.
   PubMed Web of Science ®Google Scholar
• Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12(1):48.
   PubMedGoogle Scholar
• Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLOS One. 2014;9(11):e113048.
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Connett JE, Voelker H, Lindberg SM, Westfall E, Wells JM, Lazarus SC, Criner GJ, Dransfield MT. β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol. BMJ Open. 2016;6(6). e012292. doi:10.1136/bmjopen-2016-012292.
   Google Scholar
• Huang YL, Lai CC, Wang YH, Wang CY, Wang JY, Wang HC, Yu CJ, Chen L. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2987–2996.
   PubMed Web of Science ®Google Scholar
• Liao K-M, Lin T-Y, Huang Y-B, Kuo C-C, Chen C-Y. The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. Int J Chron Obstruct Pulmon Dis. 2017;12:2573–2581. doi:10.2147/COPD.S141694.
   PubMed Web of Science ®Google Scholar
• Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339(8):489–497. doi:10.1056/NEJM199808203390801.
   PubMed Web of Science ®Google Scholar
• Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001;37(7):1950–1956.
   PubMed Web of Science ®Google Scholar
• Au DH, Bryson CL, Fan VS, Udris EM, Curtis JR, McDonell MB, Fihn SD. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med. 2004;117(12):925–931.
   PubMed Web of Science ®Google Scholar
• van Gestel YR, Hoeks SE, Sin DD, Welten GM, Schouten O, Witteveen HJ, Simsek C, Stam H, Mertens FW, Bax JJ, et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med. 2008;178(7):695–700.
   PubMed Web of Science ®Google Scholar
• Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2009;11(3):292–298. doi:10.1093/eurjhf/hfp001.
   PubMed Web of Science ®Google Scholar
• Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O'Connor CM. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol. 2013;111(4):582–587. doi:10.1016/j.amjcard.2012.10.041.
   PubMed Web of Science ®Google Scholar
• Ekström MP, Hermansson AB, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):715–720.
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Wells JM, Kinney GL, Washko GR Jr, Budoff M, Kim YI, Bailey WC, Nath H, Hokanson JE, Silverman EK, et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax. 2016;71(1):8–14.
   PubMed Web of Science ®Google Scholar
• Duffy S, Marron R, Voelker H, Albert R, Connett J, Bailey W, Casaburi R, Cooper JA Jr, Curtis JL, Dransfield M, et al. Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). Respir Res. 2017;18(1):124.
   PubMedGoogle Scholar
• Coiro S, Girerd N, Rossignol P, Ferreira JP, Maggioni A, Pitt B, Tritto I, Ambrosio G, Dickstein K, Zannad F. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. Eur J Heart Fail. 2017;19(2):271–279.
   PubMed Web of Science ®Google Scholar
• Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med. 2002;113(8):650–656.
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008;63(4):301–305.
   PubMed Web of Science ®Google Scholar
• Olenchock BA, Fonarow GG, Pan W, Hernandez A, Cannon CP. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol. 2009;103(3):295–300.
   PubMed Web of Science ®Google Scholar
• Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10):880–887.
   PubMed Web of Science ®Google Scholar
• Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549.
   PubMed Web of Science ®Google Scholar
• Quint JK, Herrett E, Bhaskaran K, Timmis A, Hemingway H, Wedzicha JA, Smeeth L. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ. 2013;347:f6650.
   PubMed Web of Science ®Google Scholar
• Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241–249.
   PubMed Web of Science ®Google Scholar
• Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2008;167(4):492–499.
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P. Biases in the observational study of beta blockers in COPD. Thorax. 2008;63(11):1026–1027.
   PubMed Web of Science ®Google Scholar
• Dong Y-H, Chang C-H, Wu L-C, Lai M-S. Use of cardioselective β-blockers and overall death and cardiovascular outcomes in patients with COPD: a population-based cohort study. Eur J Clin Pharmacol. 2016;72(10):1265–1273. doi:10.1007/s00228-016-2097-y.
   PubMed Web of Science ®Google Scholar
• Dong YH, Alcusky M, Maio V, Liu J, Liu M, Wu LC, Chang CH, Lai MS, Gagne JJ. Evidence of potential bias in a comparison of β blockers and calcium channel blockers in patients with chronic obstructive pulmonary disease and acute coronary syndrome: results of a multinational study. BMJ Open. 2017;7(3):e012997. doi:10.1136/bmjopen-2016-012997.
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P. Observational studies of inhaled corticosteroid effectiveness in COPD: lessons learned. CHEST. 2018;154(2):257–265.
   PubMed Web of Science ®Google Scholar
• Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med. 2009;9(1):32.
   PubMedGoogle Scholar
• Horita N, Miyazawa N, Kojima R, Inoue M, Ishigatsubo Y, Ueda A, Kaneko T. Statins reduce all-cause mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis of observational studies. Respir Res. 2014;15(1):80.
   PubMedGoogle Scholar
• Criner GJ, Connett JE, Aaron SD, Albert RK, Bailey WC, Casaburi R, Cooper JA Jr, Curtis JL, Dransfield MT, Han MK, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370(23):2201–2210.
   PubMed Web of Science ®Google Scholar
• Suissa S. Co-morbidity in COPD: the effects of cardiovascular drug therapies. Respiration. 2010;80(1):3–7.
   PubMed Web of Science ®Google Scholar
• Suissa S. Simvastatin in moderate-to-severe COPD. N Engl J Med. 2014;371(10):969–970.
   PubMedGoogle Scholar